Thomas Klima
Chief Operating Officer presso BLUEBIRD BIO, INC.
Patrimonio netto: 159 795 $ in data 31/03/2024
Profilo
Thomas J.
Klima is currently the Chief Operating & Commercial Officer at bluebird bio, Inc. He previously held positions as the Senior Director-Marketing at Dendreon Corp.
from 2009 to 2012, the Chief Commercial Officer & Senior Vice President at Navidea Biopharmaceuticals, Inc. from 2015 to 2017, and the Chief Commercial Officer at Gamida Cell Ltd.
from 2019 to 2020.
He obtained his undergraduate degree from Western State College of Colorado.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
BLUEBIRD BIO, INC.
0.06% | 04/03/2024 | 124 840 ( 0.06% ) | 159 795 $ | 31/03/2024 |
Posizioni attive di Thomas Klima
| Società | Posizione | Inizio |
|---|---|---|
| BLUEBIRD BIO, INC. | Chief Operating Officer | 08/08/2022 |
Precedenti posizioni note di Thomas Klima
| Società | Posizione | Fine |
|---|---|---|
| GAMIDA CELL LTD. | Corporate Officer/Principal | 01/12/2020 |
| NAVIDEA BIOPHARMACEUTICALS, INC. | Corporate Officer/Principal | 08/03/2017 |
| DENDREON CORPORATION | Sales & Marketing | 01/09/2012 |
Formazione di Thomas Klima
| Western State College of Colorado | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| NAVIDEA BIOPHARMACEUTICALS, INC. | Health Technology |
| BLUEBIRD BIO, INC. | Health Technology |
| GAMIDA CELL LTD. | Health Technology |
| Aziende private | 1 |
|---|---|
Dendreon Corp.
 Dendreon Corp. Medical SpecialtiesHealth Technology Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA. | Health Technology |
- Borsa valori
- Insiders
- Thomas Klima
